Successful treatment of mediastinal lymphomatoid granulomatosis with rituximab monotherapy

被引：40

作者：

Jordan, K ^{[1
]}

Grothey, A ^{[1
]}

Grothe, W ^{[1
]}

Kegel, T ^{[1
]}

Wolf, HH ^{[1
]}

Schmoll, HJ ^{[1
]}

机构：

[1] Univ Halle Wittenberg, D-06120 Halle Saale, Germany

来源：

EUROPEAN JOURNAL OF HAEMATOLOGY | 2005年 / 74卷 / 03期

关键词：

lymphomatoid granulomatosis; liebow granulomatosis; rituximab; EBV-associated lymphoproliferative disease; CD20; mediastinal bulk;

D O I：

10.1111/j.1600-0609.2004.00367.x

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

Lymphomatoid granulomatosis is a rare Epstein-Barr virus (EBV)-positive-B-cell lymphoproliferative disorder. Treatment options include corticosteroids, antiviral therapy, interferon-alpha and chemotherapy. However, long-term prognosis is poor and no therapeutic standard has been established yet. In a 21-year-old woman, a biopsy of mediastinal mass revealed lymphomatoid granulomatosis. Combined therapy with valganciclovir and interferon-alpha proved ineffective. In view of the CD20 expression of the tumor cells, monotherapy with rituximab was intiated. After 3 months a complete remission was achieved. Rituximab was continued for another 6 months with subsequent consolidation radiotherapy. This is the first report of an enduring complete remission (20 months) of a non-CNS lymphomatoid granulomatosis treated with rituximab.

引用

页码：263 / 266

页数：4

共 21 条

[1]

Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma [J].